Winterlight’s (OBIO CAAP 2017 Company) cognitive assessment detected significant improvement for treatment relative to placebo in Cortexyme's Phase 1B trial for Alzheimer’s disease using COR388; a bacterial protease inhibitor.
Advanced Code injection
Winterlight’s (OBIO CAAP 2017 Company) cognitive assessment detected significant improvement for treatment relative to placebo in Cortexyme's Phase 1B trial for Alzheimer’s disease using COR388; a bacterial protease inhibitor.